These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 32140943)

  • 1. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
    Wu J; Cai J
    Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for pancreatic cancer: A long and hopeful journey.
    Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
    Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future immunotherapeutic approaches in pancreatic cancer treatment.
    Farhangnia P; Khorramdelazad H; Nickho H; Delbandi AA
    J Hematol Oncol; 2024 Jun; 17(1):40. PubMed ID: 38835055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in pancreatic cancer: New hope or mission impossible?
    Jiang J; Zhou H; Ni C; Hu X; Mou Y; Huang D; Yang L
    Cancer Lett; 2019 Mar; 445():57-64. PubMed ID: 30641107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging trends in the immunotherapy of pancreatic cancer.
    Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
    Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.
    Li TJ; Wang WQ; Yu XJ; Liu L
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
    Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
    Torphy RJ; Schulick RD; Zhu Y
    Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic cancer.
    Xun J; Jiang X; Liu B; Hu Z; Liu J; Han Y; Gao R; Zhang H; Yang S; Yu X; Wang X; Yan C; Zhang Q
    Int Immunopharmacol; 2024 Sep; 139():112696. PubMed ID: 39018692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.
    Zheng R; Liu X; Zhang Y; Liu Y; Wang Y; Guo S; Jin X; Zhang J; Guan Y; Liu Y
    Front Immunol; 2024; 15():1383978. PubMed ID: 38756774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel target for combination immunotherapy in pancreatic cancer: IL-1β mediates immunosuppression in the tumour microenvironment.
    Winograd R; Simeone DM; Bar-Sagi D
    Br J Cancer; 2021 May; 124(11):1754-1756. PubMed ID: 33758330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
    Looi CK; Chung FF; Leong CO; Wong SF; Rosli R; Mai CW
    J Exp Clin Cancer Res; 2019 Apr; 38(1):162. PubMed ID: 30987642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Novel immunological characteristics and immunotherapeutic targets in pancreatic cancer.
    Khan HY; Lou Y; Sexton-Bonacci RE
    Front Immunol; 2024; 15():1428740. PubMed ID: 38887302
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
    Cifaldi L; Di Santo J; Olive D
    Front Immunol; 2020; 11():1132. PubMed ID: 32612604
    [No Abstract]   [Full Text] [Related]  

  • 15. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Turning tumors from cold to inflamed to improve immunotherapy response.
    Gerard CL; Delyon J; Wicky A; Homicsko K; Cuendet MA; Michielin O
    Cancer Treat Rev; 2021 Dec; 101():102227. PubMed ID: 34656019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontiers in cancer immunotherapy-a symposium report.
    Cable J; Greenbaum B; Pe'er D; Bollard CM; Bruni S; Griffin ME; Allison JP; Wu CJ; Subudhi SK; Mardis ER; Brentjens R; Sosman JA; Cemerski S; Zavitsanou AM; Proia T; Egeblad M; Nolan G; Goswami S; Spranger S; Mackall CL
    Ann N Y Acad Sci; 2021 Apr; 1489(1):30-47. PubMed ID: 33184911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Nanotechnology in Preclinical Pancreatic Cancer Immunotherapy: Driving Towards Clinical Applications.
    Pan X; Han T; Zhao Z; Wang X; Fang X
    Int J Nanomedicine; 2024; 19():6619-6641. PubMed ID: 38975321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
    Ibrahim AM; Wang YH
    World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.